AGIO MEXC RealStocks
Own real AGIO shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:00:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Agios Pharmaceuticals, Inc. (AGIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $29.68, with a market capitalization of $1.79B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.24 to $44.09. This page covers its latest market performance, valuation, price trends and company information.
$1.79B | |
$29.57 | |
$30.41 | |
$29.22 | |
$29.89 | |
345.87K | |
1.06M | |
-- | |
$44.09 | |
$22.24 | |
-- | |
2026-09-30 |
Agios Pharmaceuticals, Inc. (AGIO) last closed at $29.68 as of 2026-11-19 00:31:00, down 0.67% ($0.20) from the previous close of $29.89.
During the latest regular trading session, AGIO traded between $29.22 and $30.41, with a volume of 345.87K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Agios Pharmaceuticals, Inc. (AGIO) moved from $31.76 to $29.68, representing a decline of 6.56% ($2.09).
The stock traded between $28.95 and $33.12 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 646.29 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 34.0%
AGIO is currently trading at $29.68, placing it 34.0% of the way from its 52-week low of $22.24 to its 52-week high of $44.09. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 540 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Agios Pharmaceuticals, Inc. (AGIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AGIO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AGIO shares and USD.
AGIO Shares to USD
1.00 AGIO shares = 29.675 USD
Calculations are estimates based on the latest available price and are for reference only.